2014 Ablation Arrhythmia 
DAIC
MARCH 5, 2024
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation ( AF ) using pulsed field ablation (PFA).
Circulation
NOVEMBER 29, 2023
Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.StructureAtrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally.
Ken Grauer, MD
MARCH 29, 2023
While medical trial of an antiarrhythmic agent can at times be undertaken ( assuming the clinician remains at the bedside throughout the process ) — synchronized cardioversion is often favored for treatment of AFib with WPW, given the exceedingly rapid ventricular response with this arrhythmia. What do YOU see?
Cardiometabolic Health Congress
DECEMBER 7, 2023
These new guidelines provide necessary updates to both the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation and the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation.
Dr. Smith's ECG Blog
OCTOBER 13, 2022
3] So a patient with WPW can have the pattern induced by ischemia, and there is also a report of a patient with pre-existing WPW which was “ablated” by myocardial infarction after an LAD occlusion.[4] CMAJ 2014. Electrocardiography in the patient with the Wolff-Parkinson-White syndrome: diagnostic and initial therapeutic issues.
Expert insights. Personalized for you.
59 
Let's personalize your content